Scorpius BioManufacturing Announces New Microbial Capacity and New Interim President
In addition to a new interim president, the company is opening new microbial capacity at its San Antonio facility and has plans to construct a commercial-scale facility in Manhattan, Kan.
Scorpius BioManufacturing, a contract research and contract development and manufacturing organization based in Texas, announced on March 21, 2023 that the company has appointed Gary Welch as interim president. Welch will lead the company in serving clients with mammalian and microbial biologics and new modalities. Welch, who has previously worked with AbbVie, Agensys, and CytomX, comes to the company with more than 30 years of experience.
The company also announced that it will open new microbial capacity to supplement the mammalian suites at its San Antonio facility. In addition, the company plans to construct a commercial-scale facility in Manhattan, Kan. to help their clients that are creating new microbial and mammalian modalities to start projects quickly and utilize Scorpius throughout the lifecycle of those modalities.
Source: Scorpius
